Patent · US Active

Antigen receptors and uses thereof

US11702631B2 · kind B2 · utility

0Cited by

1References

15Claims

0Family size

Assignees

TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz · DE
BioNTech Cell & Gene Therapies GmbH · DE

Inventors

Ralf-Holger Voss · Ingelheim am Rhein, DE
Ugur Sahin · Mainz, DE
Petra OEHM · Mainz, DE
Matthias BIRTEL · Mainz, DE
Janina Caspar · Waldalgesheim, DE

Key dates

Filing date	Mar 14, 2018
Grant date	Jul 18, 2023
Priority date	—
Expiry date	Mar 21, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/70
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to recombinant antigen receptors and uses thereof. T cells engineered to express such antigen receptors are useful in the treatment of diseases characterized by expression of one or more antigens bound by the antigen receptors.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.